Melkersson-Rosenthal Syndrome in a Patient with Psoriatic Arthritis Receiving Etanercept. (January 2013)

• Record Type: Journal Article
• Authors: Gaudio, A.; Corrado, A.; Santoro, N.; Maruotti, N.; Cantatore, F.P.
• Is Part Of: International journal of immunopathology and pharmacology. Volume 26:Number 1(2013)
• Page Start: 229
• Page End: 233
• Publication Date: 2013-01
• Subjects: granulomatous disease -- psoriatic arthritis -- sarcoidosis -- TNF; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/039463201302600123
• Languages: English
• ISSNs: 0394-6320

Abstract

Melkersson-Rosenthal syndrome is a rare granulomatous neuro-mucocutaneous systemic disease that is characterized by relapsing peripheral facial paralysis, orofacial edema and fissured tongue. The disease etiology is still not well known, but it has been hypothesized that a possible role is played by various causal agents such as infectious diseases, genetic causes, allergic conditions, benign lymphogranulomatosis, various associations with other pathological conditions, particularly with immune-mediated diseases and food contact allergies. In this report we describe the case of a woman, 42 years old, with psoriatic arthritis who developed neurological episodes related to MRS after treatment with anti-TNF therapy. This finding further supports the hypothesis that TNF-α blockade, and particularly the use of the TNF-α receptor, could trigger the development of granulomatous lesions in predisposed patients. The case we report further sustains the importance for the clinician to take into account this potential adverse event in patients receiving anti-TNF-α therapies.